Clinical Trial Update: A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing efficacy, safety, and durability of Faricimab in neovascular age-related macular degeneration; trial is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Status: ACTIVE_NOT_RECRUITING